224 related articles for article (PubMed ID: 31403868)
1. Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Pujade-Lauraine E; Banerjee S; Pignata S
J Clin Oncol; 2019 Sep; 37(27):2437-2448. PubMed ID: 31403868
[No Abstract] [Full Text] [Related]
2. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
3. Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.
Bouberhan S; Pujade-Lauraine E; Cannistra SA
J Clin Oncol; 2019 Sep; 37(27):2424-2436. PubMed ID: 31403861
[No Abstract] [Full Text] [Related]
4. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
6. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
7. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
8. Targeting Programmed Cell Death 1 in Ovarian Cancer.
Homicsko K; Coukos G
J Clin Oncol; 2015 Dec; 33(34):3987-9. PubMed ID: 26503205
[No Abstract] [Full Text] [Related]
9. Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine.
Komiyama S; Kugimiya T; Takeya C; Takahashi R; Kubushiro K
J Obstet Gynaecol Res; 2018 Jul; 44(7):1330-1334. PubMed ID: 29767464
[TBL] [Abstract][Full Text] [Related]
10. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
Modesitt SC; Jazaeri AA
Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
[TBL] [Abstract][Full Text] [Related]
11. The problem with platinum.
Holmes D
Nature; 2015 Nov; 527(7579):S218-9. PubMed ID: 26605762
[No Abstract] [Full Text] [Related]
12. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
13. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with relapsed/refractory metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):14-16. PubMed ID: 31730591
[No Abstract] [Full Text] [Related]
15. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
16. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer.
Nguyen TT; Wright JD; Powell MA; Gibb RK; Rader JS; Allsworth JE; Mutch DG
Int J Gynecol Cancer; 2008; 18(6):1194-9. PubMed ID: 18217964
[TBL] [Abstract][Full Text] [Related]
18. Ovarian Cancer Treatment Stratification Using
Lohse I; Azzam DJ; Al-Ali H; Volmar CH; Brothers SP; Ince TA; Wahlestedt C
Anticancer Res; 2019 Aug; 39(8):4023-4030. PubMed ID: 31366484
[TBL] [Abstract][Full Text] [Related]
19. Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.
Rutherford SC; Leonard JP
JAMA Oncol; 2018 Aug; 4(8):1120-1121. PubMed ID: 30003234
[No Abstract] [Full Text] [Related]
20. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]